Prostate cancer in transgender women.
暂无分享,去创建一个
[1] Ze Chen,et al. Breast and reproductive cancers in the transgender population: a systematic review , 2018, BJOG : an international journal of obstetrics and gynaecology.
[2] A. Kishan,et al. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer , 2018, JAMA.
[3] Ariella R. Tabaac,et al. Gender Identity Disparities in Cancer Screening Behaviors. , 2018, American journal of preventive medicine.
[4] Liangyuan Hu,et al. Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Chin-Lee Wu,et al. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α‐reductase 2 , 2017, The Journal of pathology.
[6] P. Cohen-Kettenis,et al. Endocrine Treatment of Gender‐Dysphoric/Gender‐Incongruent Persons: An Endocrine Society* Clinical Practice Guideline , 2017, The Journal of clinical endocrinology and metabolism.
[7] Todd McNutt,et al. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. , 2017, International journal of radiation oncology, biology, physics.
[8] L. Kovacs,et al. Combined vaginoplasty technique for male-to-female sex reassignment surgery: Operative approach and outcomes. , 2017, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[9] R. Autorino,et al. Prostate Cancer in Transgender Women: Incidence, Etiopathogenesis, and Management Challenges. , 2017, Urology.
[10] M. Parmar,et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.
[11] G. Prins,et al. The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? , 2017, The Prostate.
[12] J. Safer,et al. What Surgeons Need to Know About Gender Confirmation Surgery When Providing Care for Transgender Individuals: A Review , 2017, JAMA surgery.
[13] V. Dalton,et al. Transgender Demographics: A Household Probability Sample of US Adults, 2014. , 2017, American journal of public health.
[14] Stephen Whittle,et al. Transgender people: health at the margins of society , 2016, The Lancet.
[15] S. Reisner,et al. Beyond Bathrooms--Meeting the Health Needs of Transgender People. , 2016, The New England journal of medicine.
[16] E. Coleman,et al. Barriers to healthcare for transgender individuals , 2016, Current opinion in endocrinology, diabetes, and obesity.
[17] M. Matrana,et al. Metastatic Prostate Cancer 35 Years After Sex Reassignment Surgery. , 2016, Clinical genitourinary cancer.
[18] L. Gooren,et al. Sex reassignment of transsexual people from a gynecologist's and urologist's perspective , 2015, Acta obstetricia et gynecologica Scandinavica.
[19] L. Gooren,et al. Prostate cancer incidence in orchidectomised male‐to‐female transsexual persons treated with oestrogens , 2014, Andrologia.
[20] P. V. van Diest,et al. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. , 2013, The journal of sexual medicine.
[21] S. Reisner,et al. Experiences of transgender-related discrimination and implications for health: results from the Virginia Transgender Health Initiative Study. , 2013, American journal of public health.
[22] S. Prescott,et al. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[23] C. Beyrer,et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. , 2013, The Lancet. Infectious diseases.
[24] W. J. Meyer,et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 , 2012 .
[25] J. Snelgrove,et al. “Completely out-at-sea” with “two-gender medicine”: A qualitative analysis of physician-side barriers to providing healthcare for transgender patients , 2012, BMC Health Services Research.
[26] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[27] C. L. Cutajar,et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.
[28] Z. Nugent,et al. The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team. , 2010, Brachytherapy.
[29] A. Danoff,et al. Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. , 2009, American journal of public health.
[30] R. Miksad,et al. DETECTION OF PROSTATE CANCER FOLLOWING GENDER REASSIGNMENT , 2007, BJU international.
[31] T. Dorff,et al. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. , 2007, Clinical genitourinary cancer.
[32] I. Kaplan,et al. Prostate cancer in a transgender woman 41 years after initiation of feminization. , 2006, JAMA.
[33] D. Newling,et al. Metastatic prostatic carcinoma in a male-to-female transsexual. , 1998, British journal of urology.
[34] A. Thurston. Carcinoma of the prostate in a transsexual. , 1994, British journal of urology.
[35] S. Winter. Lost in transition: transgender people,. Rights and HIV vulnerability in the Asia-Pacific region , 2012 .
[36] C. Markland. Transexual surgery. , 1975, Obstetrics and gynecology annual.